Drospirenone and ethinyl estradiol + Placebo
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Premenstrual Syndrome
Conditions
Premenstrual Syndrome, Depression
Trial Timeline
Feb 1, 2008 → May 1, 2011
NCT ID
NCT00633360About Drospirenone and ethinyl estradiol + Placebo
Drospirenone and ethinyl estradiol + Placebo is a pre-clinical stage product being developed by Bayer for Premenstrual Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00633360. Target conditions include Premenstrual Syndrome, Depression.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00633360 | Pre-clinical | Completed |
Competing Products
5 competing products in Premenstrual Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| paroxetine | Novo Nordisk | Approved | 84 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levetiracetam | UCB | Pre-clinical | 20 |
| EE20/DRSP(YAZ, BAY86-5300) + Placebo | Bayer | Phase 3 | 74 |